Stock Research for PTCT

PTCT

Featured Broker: Ally Invest

Get the due diligence for another stock.

 

PTCT Stock Chart & Research Data

The PTCT chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the PTCT chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


 


PTCT Due diligence Resources & Stock Charts

The PTCT stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View PTCT Detailed Price Forecast - CNN Money CNN View PTCT Detailed Summary - Google Finance
Yahoo View PTCT Detailed Summary - Yahoo! Finance Zacks View PTCT Stock Research & Analysis - Zacks.com

Stock Analysis

TradeIdeas View PTCT Trends & Analysis - Trade-Ideas Barrons View PTCT Major Holders - Barrons
NASDAQ View PTCT Call Transcripts - NASDAQ Seeking View PTCT Breaking News & Analysis - Seeking Alpha
Spotlight View PTCT Annual Report - CompanySpotlight.com OTC Report View PTCT OTC Short Report - OTCShortReport.com
TradeKing View PTCT Fundamentals - TradeKing Charts View PTCT SEC Filings - Bar Chart
WSJ View Historical Prices for PTCT - The WSJ Morningstar View Performance/Total Return for PTCT - Morningstar
MarketWatch View the Analyst Estimates for PTCT - MarketWatch CNBC View the Earnings History for PTCT - CNBC
StockMarketWatch View the PTCT Earnings - StockMarketWatch MacroAxis View PTCT Buy or Sell Recommendations - MacroAxis
Bullish View the PTCT Bullish Patterns - American Bulls Short Pains View PTCT Short Pain Metrics - ShortPainBot.com

Social Media Mentions

StockTwits View PTCT Stock Mentions - StockTwits PennyStocks View PTCT Stock Mentions - PennyStockTweets
Twitter View PTCT Stock Mentions - Twitter Invest Hub View PTCT Investment Forum News - Investor Hub
Yahoo View PTCT Stock Mentions - Yahoo! Message Board Seeking Alpha View PTCT Stock Mentions - Seeking Alpha


Financial & Transaction Holdings

SECform4 View Insider Transactions for PTCT - SECform4.com Insider Cow View Insider Transactions for PTCT - Insider Cow
CNBC View PTCT Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for PTCT - OTC Markets
Yahoo View Insider Transactions for PTCT - Yahoo! Finance NASDAQ View Institutional Holdings for PTCT - NASDAQ


Stock Charts

FinViz View PTCT Stock Insight & Charts - FinViz.com StockCharts View PTCT Investment Charts - StockCharts.com
BarChart View PTCT Stock Overview & Charts - BarChart Trading View View PTCT User Generated Charts - Trading View




Latest Financial News for PTCT


A Comprehensive Look at Sarepta's Growth and Innovation
Posted on Monday March 25, 2024

One of the leaders in the global DMD drugs market is expected to outperform


Biotech Stock Roundup: GERN, CRNX Gain on Updates, BMY's CAR T Cell Therapy News & More
Posted on Thursday March 21, 2024

Geron Corporation (GERN) and Crinetics Pharmaceuticals (CRNX) gain on positive regulatory and study updates.


PTC Therapeutics (PTCT) Up on Positive Regulatory Updates
Posted on Wednesday March 20, 2024

PTC Therapeutics (PTCT) submits BLA for gene therapy Upstaza to the FDA and announces plans to resubmit its application for Translarna to the regulatory body. Its shares rise on these updates.


PTC Therapeutics Provides Key Regulatory Updates
Posted on Tuesday March 19, 2024

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the submission of a BLA to the U.S. FDA for Upstaza™ (eladocagene exuparvovec), a gene therapy for the treatment of aromatic L-amino acid decarboxylase (AADC) deficiency. In addition, based on recent feedback from the FDA, PTC plans to re-submit an NDA for Translarna™ (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD). PTC expects to make the NDA resubmission by mid-year.


Stock Market & Investing Books

Enter a stock symbol to view the stock details.